1
|
Qiu J, Fan X, Ding H, Zhao M, Xu T, Lei J, Ji B, Zhuang Z, Gao Q. Antenatal dexamethasone retarded fetal long bones growth and development by down-regulating of insulin-like growth factor 1 signaling in fetal rats. Hum Exp Toxicol 2022; 41:9603271211072870. [PMID: 35148621 DOI: 10.1177/09603271211072870] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
OBJECTIVE Dexamethasone (DEX), a synthetic glucocorticoid, has been widely used as a medication for premature delivery. However, the side effects of antenatal DEX treatment on fetal bone development, as well as the underlying mechanisms still remain to be elucidated. Here, we aimed to explore the effects and the related mechanisms of antenatal DEX exposure during late pregnancy on fetal bone growth and development. METHODS Pregnant Sprague-Dawley rats were randomly divided into DEX group and vehicle group from gestational day 14 (GD14). Pregnant rats in DEX group were intraperitoneally injected once with DEX (200 µg/kg body weight) on GD14, 16, 18, and 20. The vehicle group rats were administered the same amount of normal saline at the same time. Pregnant rats were anesthetized at GD21 to harvest fetal femurs for analysis. RESULTS Antenatal DEX treatment delayed fetal skeletal growth via inhibiting extracellular matrix (ECM) synthesis and downregulating insulin-like growth factor 1 (IGF1) signaling. Several components of IGF1 signaling pathway, including IGF1 receptor, insulin receptor substrate, as well as serine-threonine protein kinase, were down-regulated in fetal growth plate chondrocytes following DEX treatment. CONCLUSION This study indicated that antenatal DEX treatment-retarded fetal skeletal growth was associated with the down-regulation of IGF1 signaling in growth plate chondrocytes, providing important information about the impact of antenatal DEX application four courses on premature infant.
Collapse
Affiliation(s)
- Junlan Qiu
- Institute for Fetology, 74566First Hospital of Soochow University, Suzhou, China.,Department of Oncology, 105860Second Affiliated Hospital of Soochow University, Suzhou, China.,Department of Oncology and Hematology, Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical University, Suzhou, China
| | - Xiaorong Fan
- Institute for Fetology, 74566First Hospital of Soochow University, Suzhou, China.,Institute of Reproductive Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Hongmei Ding
- Institute for Fetology, 74566First Hospital of Soochow University, Suzhou, China
| | - Meng Zhao
- Institute for Fetology, 74566First Hospital of Soochow University, Suzhou, China
| | - Ting Xu
- Institute for Fetology, 74566First Hospital of Soochow University, Suzhou, China
| | - Jiahui Lei
- Institute for Fetology, 74566First Hospital of Soochow University, Suzhou, China
| | - Bingyu Ji
- Institute for Fetology, 74566First Hospital of Soochow University, Suzhou, China
| | - Zhixiang Zhuang
- Department of Oncology, 105860Second Affiliated Hospital of Soochow University, Suzhou, China
| | - Qinqin Gao
- Institute for Fetology, 74566First Hospital of Soochow University, Suzhou, China
| |
Collapse
|
2
|
Tomaszewska E, Burmańczuk N, Dobrowolski P, Świątkiewicz M, Donaldson J, Burmańczuk A, Mielnik-Błaszczak M, Kuc D, Milewski S, Muszyński S. The Protective Role of Alpha-Ketoglutaric Acid on the Growth and Bone Development of Experimentally Induced Perinatal Growth-Retarded Piglets. Animals (Basel) 2021; 11:E137. [PMID: 33435211 PMCID: PMC7826854 DOI: 10.3390/ani11010137] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Revised: 01/07/2021] [Accepted: 01/08/2021] [Indexed: 01/01/2023] Open
Abstract
The effect of alpha-ketoglutaric acid (AKG) supplementation to experimentally-induced, perinatal growth-retarded piglets was examined. Sows were treated with a synthetic glucocorticoid (Gc) during the last 25 days of pregnancy, and after the birth, piglets were randomly divided into three groups depending on the treatment. The Gc/Gc + AKG and Gc/AKG groups born by Gc-treated sows after the birth were treated with Gc or Gc + AKG for 35 days. Significantly lower serum growth hormone, IGF-I, osteocalcin, leptin, and cortisol concentrations were observed in the Gc/Gc + AKG group, while the bone alkaline phosphatase activity was significantly higher. Serum insulin concentration was higher in the control group. Serum alanine, lysine, histidine, and tryptophan concentrations were higher in the Gc/Gc + AKG and Gc/AKG groups. The perinatal action of Gc significantly affects histomorphometry of articular cartilage and trabecular bone and bone mechanics. The results clearly showed that dietary AKG had positive effects with regards to the profile of free amino acids. Taking into account the function of AKG as an energy donor and stimulator of collagen synthesis, it can be concluded that the anabolic role of AKG may be the main mechanism responsible for its protective effect against the GC-induced perinatal intensified catabolic state.
Collapse
Affiliation(s)
- Ewa Tomaszewska
- Department of Animal Physiology, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Akademicka St. 12, 20-950 Lublin, Poland;
| | - Natalia Burmańczuk
- Department of Animal Physiology, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Akademicka St. 12, 20-950 Lublin, Poland;
| | - Piotr Dobrowolski
- Department of Functional Anatomy and Cytobiology, Faculty of Biology and Biotechnology, Maria Curie-Sklodowska University, Akademicka St. 19, 20-033 Lublin, Poland;
| | - Małgorzata Świątkiewicz
- Department of Animal Nutrition and Feed Science, National Research Institute of Animal Production, Krakowska St. 1, 32-083 Balice, Poland;
| | - Janine Donaldson
- Faculty of Health Sciences, School of Physiology, University of the Witwatersrand, 7 York Road, Parktown, Johannesburg 2193, South Africa;
| | - Artur Burmańczuk
- Faculty of Veterinary Medicine, Institute of Preclinical Veterinary Sciences, University of Life Sciences in Lublin, Akademicka St. 12, 20-950 Lublin, Poland;
| | - Maria Mielnik-Błaszczak
- Department of Developmental Dentistry, Medical University of Lublin, 7 Karmelicka St., 20-081 Lublin, Poland; (M.M.-B.); (D.K.)
| | - Damian Kuc
- Department of Developmental Dentistry, Medical University of Lublin, 7 Karmelicka St., 20-081 Lublin, Poland; (M.M.-B.); (D.K.)
| | - Szymon Milewski
- Department of Biophysics, Faculty of Environmental Biology, University of Life Sciences in Lublin, Akademicka St. 13, 20-950 Lublin, Poland; (S.M.); (S.M.)
| | - Siemowit Muszyński
- Department of Biophysics, Faculty of Environmental Biology, University of Life Sciences in Lublin, Akademicka St. 13, 20-950 Lublin, Poland; (S.M.); (S.M.)
| |
Collapse
|
3
|
Schulz EV, Wagner CL. History, epidemiology and prevalence of neonatal bone mineral metabolic disorders. Semin Fetal Neonatal Med 2020; 25:101069. [PMID: 31952927 DOI: 10.1016/j.siny.2019.101069] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The evolutionary patterns of human migration and historical pre/post-industrial revolution have changed the face of bone metabolic disease through past centuries. Cultural, religious, and lifestyle practices continue to alter nutritional recommendations for this expanding diagnosis. Likewise, modern advancements in the field of neonatology and, more specifically, aggressive nutritional management of premature infants have shaped the epidemiology of neonatal bone metabolism over the past two decades. Decreased use of long-term parenteral nutrition, early fortification of enteral nutrition, and stringent American Academy of Pediatrics (AAP) practice guidelines instituting early supplementation of vitamin D have attributed to improved bone mineralization outcomes in both term and preterm infants. Nevertheless, neonatal bone mineral metabolic disorders remain prevalent. In this review, we provide an in-depth look at the diagnoses, therapeutics, and subset populations-both genetic and non-genetic-affected by neonatal bone mineral metabolic disorders.
Collapse
Affiliation(s)
- Elizabeth V Schulz
- Department of Pediatrics, Medical University of South Carolina, 165 Ashley Avenue, MSC 917, Charleston, SC, 29425, USA.
| | - Carol L Wagner
- Department of Pediatrics, Medical University of South Carolina, 165 Ashley Avenue, MSC 917, Charleston, SC, 29425, USA.
| |
Collapse
|
4
|
Mól N, Zasada M, Kwinta P. Does type of feeding affect body composition in very low birth weight infants? - A prospective cohort study. Pediatr Neonatol 2019; 60:135-140. [PMID: 29784603 DOI: 10.1016/j.pedneo.2018.04.010] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Revised: 09/18/2017] [Accepted: 04/30/2018] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND The aim of the study was to analyse body composition of preterm infants fed with either breast milk or formula compared to a control group of full-term newborns. METHODS Fifty-three newborns were enrolled: a group of 34 very low birth weight (VLBW) preterm newborns subdivided into a formula-fed (n = 23; group A) and breast milk-fed (n = 11; group B) group, and a control group of 19 full-term infants (group C). Their body composition was assessed by a bioelectrical impedance analysis (BIA) either at the estimated time of birth in the VLBW group or during the 1st week of life in the full-term group. RESULTS There was no difference in body weight or length between any of the three studied groups. However, we discovered that fat free mass (% FFM) was lower (83.5% vs. 85.5%; p < 0.01), while fat mass (% FM) was higher (16.4% vs.14.5%; p < 0.01) in group A compared to full-term newborns. There were no such differences in FFM (84.3% vs. 85.5%; p = 0.13) or FM (15.7% vs. 14.5%; p = 0.13) between group B and control. CONCLUSION To sum up, the VLBW infants fed with breast milk shared similar body composition with the full-term infants, while the formula-fed VLBW developed higher amounts of adipose tissue and lower amounts of fat-free mass. This is the first study to expose differences in fat tissue content attributed to type of provided nutrition, which has become significant as early as estimated time of birth despite the comparable weight.
Collapse
Affiliation(s)
- Nina Mól
- Department of Paediatrics, Institute of Paediatrics, Faculty of Medicine, Jagiellonian University Medical College, Wielicka 265, 30-663, Krakow, Poland.
| | - Magdalena Zasada
- Department of Paediatrics, Institute of Paediatrics, Faculty of Medicine, Jagiellonian University Medical College, Wielicka 265, 30-663, Krakow, Poland
| | - Przemko Kwinta
- Department of Paediatrics, Institute of Paediatrics, Faculty of Medicine, Jagiellonian University Medical College, Wielicka 265, 30-663, Krakow, Poland
| |
Collapse
|
5
|
Wagner K, Wagner S, Susi A, Gorman G, Hisle-Gorman E. Prematurity Does Not Increase Early Childhood Fracture Risk. J Pediatr 2019; 207:148-153. [PMID: 30528571 DOI: 10.1016/j.jpeds.2018.11.017] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2018] [Revised: 10/17/2018] [Accepted: 11/06/2018] [Indexed: 12/12/2022]
Abstract
OBJECTIVE To evaluate the impact of prematurity on fracture by age 5, controlling for medications and comorbidities of prematurity. STUDY DESIGN We performed a retrospective cohort study of infants born in Military Treatment Facilities in 2009-2010 with ≥5 years of follow-up care. Gestational age, low birth weight, comorbidities of prematurity (osteopenia, necrotizing enterocolitis, chronic lung disease, and cholestasis) and fractures were identified by International Classification of Disease, 9th Edition, codes. Pharmaceutical records identified treatment with caffeine, diuretics, postnatal corticosteroids, and antacids. Poisson regression analysis determined fracture rate by 5 years of life. RESULTS There were 65 938 infants born in 2009-2010 who received care in the military health system for ≥5 years, including 3589 born preterm; 165 born at ≤286/7 weeks of gestation, 380 born at 29-316/7 weeks of gestation, and 3044 born at 32-366/7 weeks of gestation. Preterm birth at any gestational age was not associated with fracture rate in adjusted models. The fracture rate was increased with cholestasis, proton pump inhibitor exposure, and male sex. CONCLUSIONS Prematurity was not associated with fracture rate. Neonatal cholestasis and proton pump inhibitor treatment were associated with increased fractures by age 5.
Collapse
Affiliation(s)
- Kari Wagner
- Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD; Department of Pediatrics, Uniformed Services University, Bethesda, MD
| | - Scott Wagner
- Department of Orthopedic Surgery, Walter Reed National Military Medical Center, Bethesda, MD; Department of Orthopedic Surgery, Uniformed Services University, Bethesda, MD
| | - Apryl Susi
- Department of Pediatrics, Uniformed Services University, Bethesda, MD
| | - Gregory Gorman
- Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD; Department of Pediatrics, Uniformed Services University, Bethesda, MD
| | | |
Collapse
|
6
|
Chen Z, Zhao X, Li Y, Zhang R, Nie Z, Cheng X, Zhang X, Wang H. Course-, dose-, and stage-dependent toxic effects of prenatal dexamethasone exposure on long bone development in fetal mice. Toxicol Appl Pharmacol 2018; 351:12-20. [PMID: 29753006 DOI: 10.1016/j.taap.2018.05.005] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2017] [Revised: 05/06/2018] [Accepted: 05/07/2018] [Indexed: 01/19/2023]
Abstract
Dexamethasone is routinely used for treating those mothers at risk for preterm delivery. However, overexposure to exogenous glucocorticoids induces bone loss in offspring, and the "critical window" and safe dose of this treatment are largely unknown. In this study, we found that femoral length, and the length of the primary ossification center were significantly reduced in fetal mice after repeated prenatal dexamethasone exposure (PDE). Compared with single-course exposure on gestational day (GD)15, newborn mice with repeated PDE (3 times, from GD15 to 17) showed a significant decrease in femoral trabecular bone mass with decreased trabecular number and thickness. For those newborn mice treated after repeated PDE at different doses (0, 0.2, 0.8, and 1.2 mg/kg/d), the toxic effect of dexamethasone on bone development was observed at 0.8 and 1.2 mg/kg/d. More severe retardation in bone development was observed in the fetal mice after PDE at 0.8 mg/kg/d during GD12-14, compared with that during GD15-17. Interestingly, stronger toxic effects were observed in male newborn mice after PDE than were observed in female newborn mice. In conclusion, PDE with multiple course, higher dose, or exposure at an early stage of pregnancy have stronger toxic effects on bone development of fetal mice.
Collapse
Affiliation(s)
- Ze Chen
- Department of Pharmacology, Basic Medical School of Wuhan University, No.185 Donghu Road, Wuhan, Hubei Province 430071, China
| | - Xin Zhao
- Department of Physiology, Basic Medical School of Wuhan University, No.185 Donghu Road, Wuhan, Hubei Province 430071, China
| | - Yunzepeng Li
- Department of Pharmacology, Basic Medical School of Wuhan University, No.185 Donghu Road, Wuhan, Hubei Province 430071, China
| | - Rui Zhang
- Department of Pharmacology, Basic Medical School of Wuhan University, No.185 Donghu Road, Wuhan, Hubei Province 430071, China
| | - Zaihui Nie
- Department of Pharmacology, Basic Medical School of Wuhan University, No.185 Donghu Road, Wuhan, Hubei Province 430071, China
| | - Xiang Cheng
- Department of Pharmacology, Basic Medical School of Wuhan University, No.185 Donghu Road, Wuhan, Hubei Province 430071, China
| | - Xianrong Zhang
- Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, No.1838, North of Guangzhou Avenue, Guangzhou, Guangdong Province 510515, China; Guangdong Provincial Key Laboratory of Bone and Cartilage Regenerative Medicine, Nanfang Hospital, Southern Medical University, No.1838, North of Guangzhou Avenue, Guangzhou, Guangdong Province 510515, China.
| | - Hui Wang
- Department of Pharmacology, Basic Medical School of Wuhan University, No.185 Donghu Road, Wuhan, Hubei Province 430071, China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, No.185 Donghu Road, Wuhan, Hubei Province 430071, China.
| |
Collapse
|
7
|
Abstract
Preterm infants with lung disease present nutrition challenges to health care providers. Malnutrition is common, develops shortly after birth, and may continue into early childhood. Although there are many studies identifying the nutrient deficiencies in infants with chronic lung disease, few randomized trials have explored the effects of nutrition support on the prevention and treatment of chronic lung disease. The purpose of this article is to review current practices and ongoing controversies in the nutrition management of infants with chronic lung disease.
Collapse
Affiliation(s)
- Susan J Carlson
- Children's Hospital of Iowa at The University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
| |
Collapse
|
8
|
Dobrowolski P, Tomaszewska E, Muszyński S, Blicharski T, Pierzynowski SG. Dietary 2-oxoglutarate prevents bone loss caused by neonatal treatment with maximal dexamethasone dose. Exp Biol Med (Maywood) 2017; 242:671-682. [PMID: 28178857 DOI: 10.1177/1535370217693322] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Synthetic glucocorticoids (GCs) are widely used in the variety of dosages for treatment of premature infants with chronic lung disease, respiratory distress syndrome, allergies, asthma, and other inflammatory and autoimmune conditions. Yet, adverse effects such as glucocorticoid-induced osteoporosis and growth retardation are recognized. Conversely, 2-oxoglutarate (2-Ox), a precursor of glutamine, glutamate, and collagen amino acids, exerts protective effects on bone development. Our aim was to elucidate the effect of dietary administered 2-Ox on bone loss caused by neonatal treatment with clinically relevant maximal therapeutic dexamethasone (Dex) dose. Long bones of neonatal female piglets receiving Dex, Dex+2-Ox, or untreated were examined through measurements of mechanical properties, density, mineralization, geometry, histomorphometry, and histology. Selected hormones, bone turnover, and growth markers were also analyzed. Neonatal administration of clinically relevant maximal dose of Dex alone led to over 30% decrease in bone mass and the ultimate strength ( P < 0.001 for all). The length (13 and 7% for femur and humerus, respectively) and other geometrical parameters (13-45%) decreased compared to the control ( P < 0.001 for all). Dex impaired bone growth and caused hormonal imbalance. Dietary 2-Ox prevented Dex influence and vast majority of assessed bone parameters were restored almost to the control level. Piglets receiving 2-Ox had heavier, denser, and stronger bones; higher levels of growth hormone and osteocalcin concentration; and preserved microarchitecture of trabecular bone compared to the Dex group. 2-Ox administered postnatally had a potential to maintain bone structure of animals simultaneously treated with maximal therapeutic doses of Dex, which, in our opinion, may open up a new opportunity in developing combined treatment for children treated with GCs. Impact statement The present study has showed, for the first time, that dietary 2-oxoglutarate (2-Ox) administered postnatally has a potential to improve/maintain bone structure of animals simultaneously treated with maximal therapeutic doses of dexamethasone (Dex). It may open the new direction in searching and developing combined treatment for children treated with glucocorticoids (GCs) since growing group of children is exposed to synthetic GCs and adverse effects such as glucocorticoid-induced osteoporosis and growth retardation are recognized. Currently proposed combined therapies have numerous side effects. Thus, this study proposed a new direction in combined therapies utilizing dietary supplementation with glutamine derivative. Impairment caused by Dex in presented long bones animal model was prevented by dietary supplementation with 2-Ox and vast majority of assessed bone parameters were restored almost to the control level. These results support previous thesis on the regulatory mechanism of nutrient utilization regulated by glutamine derivatives and enrich the nutritional science.
Collapse
Affiliation(s)
- Piotr Dobrowolski
- 1 Department of Comparative Anatomy and Anthropology, Maria Curie-Skłodowska University, Lublin 20-033, Poland
| | - Ewa Tomaszewska
- 2 Department of Biochemistry and Animal Physiology, Faculty of Veterinary Medicine, The University of Life Sciences in Lublin, Lublin 20-033, Poland
| | - Siemowit Muszyński
- 3 Department of Physics, Faculty of Production Engineering, University of Life Sciences in Lublin, Lublin 20-950, Poland
| | - Tomasz Blicharski
- 4 Department of Rehabilitation and Orthopaedics, Medical University of Lublin, Lublin 20-954, Poland.,5 Lublin Diagnostic Centre, Swidnik 21-040, Poland
| | - Stefan G Pierzynowski
- 6 Department of Biology, Lund University, Lund 22362, Sweden.,7 Innovation Centre-Edoradca, Tczew 83-110, Poland.,8 SGPlus, Trelleborg 23132, Sweden.,9 Department of Medical Biology, Institute of Rural Health, Lublin 20-950, Poland
| |
Collapse
|
9
|
Zhang X, Shang-Guan Y, Ma J, Hu H, Wang L, Magdalou J, Chen L, Wang H. Mitogen-inducible gene-6 partly mediates the inhibitory effects of prenatal dexamethasone exposure on endochondral ossification in long bones of fetal rats. Br J Pharmacol 2016; 173:2250-62. [PMID: 27128203 DOI: 10.1111/bph.13506] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2015] [Revised: 04/05/2016] [Accepted: 04/18/2016] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND AND PURPOSE Prenatal exposure to dexamethasone slows down fetal linear growth and bone mineralization but the regulatory mechanism remains unknown. Here we assessed how dexamethasone regulates bone development in the fetus. EXPERIMENTAL APPROACH Dexamethasone (1 mg·kg(-1) ·day(-1) ) was injected subcutaneously every morning in pregnant rats from gestational day (GD)9 to GD20. Fetal femurs and tibias were harvested at GD20 for histological and gene expression analysis. Femurs of 12-week-old female offspring were harvested for microCT (μCT) measurement. Primary chondrocytes were treated with dexamethasone (10, 50, 250 and 1000 nM). KEY RESULTS Prenatal dexamethasone exposure resulted in accumulation of hypertrophic chondrocytes and delayed formation of the primary ossification centre in fetal long bone. The retardation was accompanied by reduced maturation of hypertrophic chondrocytes, decreased osteoclast number and down-regulated expression of osteocalcin and bone sialoprotein in long bone. In addition, the mitogen-inducible gene-6 (Mig6) and osteoprotegerin (OPG) expression were stimulated, and the receptor activator of NF-κB ligand (RANKL) expression was repressed. Moreover, dexamethasone activated OPG and repressed RANKL expression in both primary chondrocytes and primary osteoblasts, and the knockdown of Mig6 abolished the effect of dexamethasone on OPG expression. Further, μCT measurement showed loss of bone mass in femur of 12-week-old offspring with prenatal dexamethasone exposure. CONCLUSIONS AND IMPLICATIONS Prenatal dexamethasone exposure delays endochondral ossification by suppressing chondrocyte maturation and osteoclast differentiation, which may be partly mediated by Mig6 activation in bone. Bone development retardation in the fetus may be associated with reduced bone mass in later life.
Collapse
Affiliation(s)
- Xianrong Zhang
- Department of Physiology, School of Basic Medical Sciences, Wuhan University, Wuhan, China.,Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, China
| | - Yangfan Shang-Guan
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, China.,Department of Orthopedic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Jing Ma
- Department of Physiology, School of Basic Medical Sciences, Wuhan University, Wuhan, China.,Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, China
| | - Hang Hu
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, China.,Department of Orthopedic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Linlong Wang
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, China.,Department of Orthopedic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Jacques Magdalou
- Faculté de Médicine, UMR 7561 CNRS-NancyUniversité, Vandoeuvre-lès-Nancy, France
| | - Liaobin Chen
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, China.,Department of Orthopedic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Hui Wang
- Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, Wuhan, China.,Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, China
| |
Collapse
|
10
|
Tomaszewska E, Dobrowolski P, Siwicki A. Maternal treatment with dexamethasone at minimal therapeutic doses inhibits neonatal bone development in a gender-dependent manner. Livest Sci 2012. [DOI: 10.1016/j.livsci.2012.03.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
11
|
Sliwa E, Dobrowolski P, Piersiak T. Bone development of suckling piglets after prenatal, neonatal or perinatal treatment with dexamethasone. J Anim Physiol Anim Nutr (Berl) 2009; 94:293-306. [PMID: 19663986 DOI: 10.1111/j.1439-0396.2008.00909.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
In mammals, the release from growth-inhibiting conditions results in catch-up growth. To investigate animal evidence for whether prenatal dexamethasone (DEX) treatment leads to the development of growth restriction especially reduced mineralization of skeleton, and release from it leads to the phenomenon of catch-up, piglets were prenatally exposed to DEX (3.0 mg/sow per day(-2)) during the last 24 days of prenatal life and tested further in two different ways: discontinued at birth and continued administration of DEX (0.5 mg/kg day(-2)) to piglets through 30 days of neonatal life. Using dual energy X-ray absorptiometry methods, bone mineral density (BMD) and bone mineral content (BMC) were measured. The three-point bending test was applied to determine the mechanical properties of the bones. Furthermore, geometric properties of the bones were assessed. Serum concentration of osteocalcin (OC) was determined. Histomorphological analysis of the ribs was also performed. The consequences of neonate DEX treatment and in utero DEX exposure were reflected in a dramatic decrease of BMD, BMC and blood serum OC concentration and geometric parameters of piglets' bones. Prenatal action of DEX during the last 24 days of pregnancy resulted in continued neonatal modification of bone tissues, thus diminishing bone quality, and negatively influenced structural development and mechanical properties, finally increasing the risk of fractures of ribs and limb bones. Prenatal DEX treatment limited to the last 24 days of foetal life did not reduce the term birth weight and the growth of suckling piglets followed up to 30 days of neonatal life, and catch-up in bone mineralization did not occur.
Collapse
Affiliation(s)
- E Sliwa
- Department of Biochemistry and Animal Physiology, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Lublin, Poland.
| | | | | |
Collapse
|
12
|
Keller A, Keller E, Hermanussen M, Vogtmann C. Short-term growth of premature infants treated with dexamethasone assessed by mini-knemometry. Ann Hum Biol 2009; 31:389-97. [PMID: 15513690 DOI: 10.1080/03014460410001703727] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
AIM The study aimed to measure the direct effect of dexamethasone (DEXA) on daily lower leg length per mini-knemometry of premature infants and to examine whether the administration of different doses is associated with alternations in growth. PATIENTS AND METHODS We observed 20 premature children and had 276 complete mini-knemometrical and weight measurements (13.8 measurements per single child) for analysis. The gestational age of the infants was 26.8 +/- 1.9 weeks; the mean birth weight was 973 +/- 336 g. All infants underwent daily measurements of lower leg length performed by mini-knemometry. We divided the 41 DEXA administrations into three subgroups. Group I included a cumulative dose of 0.75 mg DEXA per kg bodyweight (BW), group II doses between 0.75 and 1.0 mg per kg BW and group III dosages above 1.0 mg per kg BW. RESULTS We observed catch-up growth in group I within 24 h after stopping therapy. Groups II and III needed 48-72 h to achieve a normal level in short-term growth. CONCLUSION Lower doses seemed to have an equivalent effect without long-term effect on lower leg length. In higher doses (groups II and III) the growth was suppressed for more than 24 h.
Collapse
Affiliation(s)
- A Keller
- Hospital of Children and Adolescents, University of Leipzig, Oststr. 21-25, 04317 Leipzig, Germany.
| | | | | | | |
Collapse
|
13
|
Mercy J, Dillon B, Morris J, Emmerson AJ, Mughal MZ. Relationship of tibial speed of sound and lower limb length to nutrient intake in preterm infants. Arch Dis Child Fetal Neonatal Ed 2007; 92:F381-5. [PMID: 17369280 PMCID: PMC2675363 DOI: 10.1136/adc.2006.105742] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Metabolic bone disease of prematurity is characterised by impaired postnatal mineralisation of the rapidly growing infant skeleton. OBJECTIVE To longitudinally evaluate postnatal changes in tibial speed of sound (tSOS; which reflects cortical thickness and bone mineral density) and lower limb length (LLL; a measure of tibial growth) in very low birthweight preterm infants receiving contemporary neonatal care. METHODS tSOS and LLL were measured using a quantitative ultrasound device and an electronic neonatal knemometer, respectively, in the same limb, weekly, for a median period of four weeks (3-16 weeks) in 84 preterm infants (median gestation 26.8 weeks (range 23-35.2 weeks) and median birth weight 869.5 g (range 418-1481 g)). RESULTS Initial tSOS and LLL were correlated with gestation (r = 0.42, p<0.001; r = 0.76, p<0.001, respectively) and birth weight (r = 0.23, p = 0.038; r = 0.93, p<0.001, respectively). Postnatally, tSOS decreased (r = -0.15, p = 0.011) whereas LLL increased (r = 0.96, p<0.001) with age. The rate of postnatal change in LLL, but not in tSOS, was positively influenced by intake of calcium (p = 0.03), phosphorus (p = 0.01) and vitamin D (p = 0.03). CONCLUSIONS The postnatal decline in tSOS, which is probably due to cortical thinning secondary to endocortical bone loss, and increase in LLL provide new insight into the development of long bones in preterm infants.
Collapse
Affiliation(s)
- J Mercy
- Department of Paediatric Medicine, St Mary's Hospital for Women & Children, Hathersage Road, Manchester M13 0JH, England.
| | | | | | | | | |
Collapse
|
14
|
Wang D, Vandermeulen J, Atkinson SA. Early life factors predict abnormal growth and bone accretion at prepuberty in former premature infants with/without neonatal dexamethasone exposure. Pediatr Res 2007; 61:111-6. [PMID: 17211151 DOI: 10.1203/01.pdr.0000250206.79628.66] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Growth, bone, and body composition were studied at prepuberty in former very low birth weight (VLBW) infants who received dexamethasone (DEX) for bronchopulmonary dysplasia (BPD) compared with VLBW infants without DEX and term-born infants (TERM) to identify early life risk factors for later low bone mass. Children (56 girls/63 boys, 5-10 y) previously studied in neonatal life were recruited into three groups: VLBW + DEX, VLBW - DEX, and TERM children. Anthropometry and whole body bone, fat, and lean mass were measured. At prepuberty, the average height and weight for VLBW + DEX group were significantly lower than that for VLBW - DEX and TERM. Both VLBW groups had lower bone mass even adjusted for height and lean mass than TERM children and lower lean mass both total and adjusted for height. Z-scores for whole body bone mineral content below -1.5 occurred in 27.9% of VLBW + DEX children. The key factors for low bone mass were earlier gestational age and having BPD with DEX in neonatal life. In former VLBW infants, growth and bone mass attainment before puberty can be predicted from early life variables. VLBW + DEX children may be protected from overweight, but are at risk for short stature and low bone mass.
Collapse
Affiliation(s)
- Dawei Wang
- Department of Pediatrics, McMaster University, Hamilton, Ontario L8N 3Z5, Canada
| | | | | |
Collapse
|
15
|
Bott L, Béghin L, Devos P, Pierrat V, Matran R, Gottrand F. Nutritional status at 2 years in former infants with bronchopulmonary dysplasia influences nutrition and pulmonary outcomes during childhood. Pediatr Res 2006; 60:340-4. [PMID: 16857773 DOI: 10.1203/01.pdr.0000232793.90186.ca] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Improved survival rates for extreme prematurity have been accompanied by an increase in the incidence of bronchopulmonary dysplasia (BPD). The objective of this study was to assess factors associated with long-term nutritional and pulmonary function outcomes. The study was a cross-sectional study of 52 children who had been born prematurely, had experienced BPD, and were 4-8 y old at the time of the study. Undernutrition was defined as a Z score for weight-for-height of <-2 SD. Body composition and lung function were evaluated. Resting energy expenditure (REE) was measured using indirect calorimetry. Stepwise logistic regression was used to test for factors associated with undernutrition and pulmonary function. Eighteen children (35%) with BPD, predominantly girls, were undernourished. Undernutrition occurred within the first months of life and was associated with high REE. Multivariate analysis showed that factors significantly associated with undernutrition were female sex and undernutrition at age 2 y. Thirty-one children (60%) had abnormal lung function tests. Multivariate analysis showed that undernutrition at age 2 y was the only factor associated with the risk of developing distension of the airways. Nutritional status at age 2 y in children who had BPD in infancy influences nutritional and pulmonary outcomes in childhood.
Collapse
Affiliation(s)
- Lucile Bott
- Department of Pediatrics, Jeanne de Flandre University Children Hospital and Faculty of Medecine, Lille 59037, France
| | | | | | | | | | | |
Collapse
|
16
|
Dalziel SR, Fenwick S, Cundy T, Parag V, Beck TJ, Rodgers A, Harding JE. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. J Bone Miner Res 2006; 21:1175-86. [PMID: 16869715 DOI: 10.1359/jbmr.060516] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
UNLABELLED Small birth size is associated with reduced adult bone mass. We determined if antenatal betamethasone exposure, birth weight, or prematurity affects peak bone mass in 174 adults. Antenatal betamethasone exposure did not. Lower birth weight and prematurity predicted reduced adult height. Slower fetal growth rather than prematurity predicted lower bone mass, but this lower bone mass was appropriate for reduced adult height. INTRODUCTION Small size at birth is reported to be associated with lower bone mass in adulthood. However, previous studies have not distinguished the relative contributions of length of gestation and fetal growth to size at birth. Fetal exposure to excess glucocorticoids has been proposed as a core mechanism underlying the associations between birth size and later disease risk. Antenatal glucocorticoids are given to pregnant women at risk for preterm delivery for the prevention of neonatal respiratory distress syndrome in their infants. We determined the relationship of antenatal exposure to betamethasone, birth weight, and prematurity to peak bone mass and femoral geometry in the adult survivors of the first randomized trial of antenatal glucocorticoids. MATERIALS AND METHODS We studied 174 young adults (mean age, 31 years) whose mothers participated in a randomized trial of antenatal betamethasone. Mothers received two doses of intramuscular betamethasone or placebo 24 h apart. Two thirds of participants were born preterm (<37 weeks gestation). We measured indices of bone mass and size and derived estimates of volumetric density and bone geometry from DXA assessments of the lumbar spine, femur, and total body. RESULTS There were no differences between betamethasone-exposed and placebo-exposed groups in any of the lumbar spine, femur, or total body DXA measures. There was no effect of antenatal betamethasone on adult height, although leg length was increased relative to trunk length (p = 0.002). A lighter birth weight (p <or = 0.001) and lower gestational age (p = 0.013) were associated with shorter stature (height Z scores) at age 31 years. Prematurity had no effect on peak bone mass or femoral geometry. However, lower birth weight, independent of gestational age, was associated with lower later bone mass (p < 0.001 for lumbar spine and total body, p = 0.003 for femoral neck BMC). These effects on bone mass were related to bone size and not to estimates of volumetric density. In the femur, lower birth weight, independent of gestational age, was associated with narrowing of the upper shaft and narrow neck regions. CONCLUSIONS Antenatal betamethasone exposure does not affect peak bone mass or femoral geometry in adulthood. Birth weight and prematurity predict adult height, but it is slower fetal growth, rather than prematurity, that predicts lower peak bone mass. The lower peak bone mass in those born small is appropriate for their adult height.
Collapse
Affiliation(s)
- Stuart R Dalziel
- Clinical Trials Research Unit, University of Auckland, Auckland, New Zealand
| | | | | | | | | | | | | |
Collapse
|
17
|
De Schepper J, Cools F, Vandenplas Y, Louis O. Whole body bone mineral content is similar at discharge from the hospital in premature infants receiving fortified breast milk or preterm formula. J Pediatr Gastroenterol Nutr 2005; 41:230-4. [PMID: 16056105 DOI: 10.1097/01.mpg.0000172883.93042.8f] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Abstract
BACKGROUND Prematurely born infants, especially those with very low birth weight (<1500 g) are at risk for metabolic bone disease. OBJECTIVES The influence of the type of oral feeding regimen and of other potential determinants of whole bone mineral content in prematurely born infants, when they approached full gestation, were evaluated. Previous studies have mainly examined effects at the level of regional bone. METHODS 34 infants (21 males and 13 females), all born between 25.4 and 33.7 weeks of gestation, were studied before discharge. Whole body bone mineral content measurements were made just before hospital discharge using a commercial densitometer (Hologic QDR 4500, Hologic Inc, Waltham, MA) at a median age of 40 days (range, 10 to 115 days) after birth. RESULTS Expressed as a percentage of whole body mass, bone mass ranged between 0.86% and 1.99%, was similar between girls and boys and correlated positively with birth weight SD (r=0.42; P<0.05) and body weight SD (r=0.35; P<0.05). No difference in bone mass percentage was found between the different types of oral feedings (fortified human milk and preterm formula) or medications studied (corticoids and diuretics). CONCLUSIONS Whereas prenatal and postnatal weight gain determines the degree of bone mineralization of premature infants, it appears that the type of oral feeding does not affect differently the postnatal bone mineralization of premature infants, when assessed at the moment of discharge.
Collapse
Affiliation(s)
- Jean De Schepper
- Department of Pediatric Endocrinology, Akademisch Ziekenhuis Vrije Universiteit Brussel, Brussels, Belgium.
| | | | | | | |
Collapse
|
18
|
Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, Tsai CH. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004; 350:1304-13. [PMID: 15044641 DOI: 10.1056/nejmoa032089] [Citation(s) in RCA: 390] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND We studied the outcomes at school age in children who had participated in a double-blind, placebo-controlled trial of early postnatal dexamethasone therapy (initiated within 12 hours after birth) for the prevention of chronic lung disease of prematurity. METHODS Of the 262 children included in the initial study, 159 lived to school age. Of these children, 146 (72 in the dexamethasone group and 74 in the control group) were included in our study. All the infants had had severe respiratory distress syndrome requiring mechanical ventilation shortly after birth. In the dexamethasone group, 0.25 mg of dexamethasone per kilogram of body weight was given intravenously every 12 hours for one week, and then the dose was tapered. We evaluated the children's growth, neurologic and motor function, cognition, and school performance. RESULTS Children in the dexamethasone group were significantly shorter than the controls (P=0.03 for boys, P=0.01 for girls, and P=0.03 for all children) and had a significantly smaller head circumference (P=0.04). Children in the dexamethasone group had significantly poorer motor skills (P<0.001), motor coordination (P<0.001), and visual-motor integration (P=0.02). As compared with the controls, children in the dexamethasone group also had significantly lower full IQ scores (mean [+/-SD], 78.2+/-15.0 vs. 84.4+/-12.6; P=0.008), verbal IQ scores (84.1+/-13.2 vs. 88.4+/-11.8, P=0.04), and performance IQ scores (76.5+/-14.6 vs. 84.5+/-12.7, P=0.001). The frequency of clinically significant disabilities was higher among children in the dexamethasone group than among controls (28 of 72 [39 percent] vs. 16 of 74 [22 percent], P=0.04). CONCLUSIONS Early postnatal dexamethasone therapy should not be recommended for the routine prevention or treatment of chronic lung disease, because it leads to substantial adverse effects on neuromotor and cognitive function at school age.
Collapse
Affiliation(s)
- Tsu F Yeh
- Department of Pediatrics, College of Medicine, China Medical University, Taichung, Taiwan.
| | | | | | | | | | | | | |
Collapse
|
19
|
Coleman MA, Honour JW. Reduced maternal dexamethasone dosage for the prenatal treatment of congenital adrenal hyperplasia. BJOG 2004; 111:176-8. [PMID: 14723758 DOI: 10.1046/j.1471-0528.2003.00040.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- M A Coleman
- Wessex Fetal and Maternal Medicine Unit, Princess Anne Hospital, Southampton, UK
| | | |
Collapse
|
20
|
Abstract
Bronchopulmonary dysplasia remains a frequent complication of extreme prematurity. In preterm neonates catch-up and pulmonary alveolar growth occur during the first two years of life. However 10 to 25% of preterm infants with bronchopulmonary dysplasia are under-nourished after two years of age, and 30 to 60% of them also suffer from persistent airway obstruction, hyperinflation and bronchial hyperreactivity. Recommendations on nutritional requirements in this population are not yet clearly defined, but an adequate nutritional status in prenatal and early postnatal period can have long-term consequences on brain and lung development. There are a few randomised trial of nutrition for preterm infants with bronchopulmonary dysplasia after discharge. Caloric and protein requirements in this population are probably higher than in full-term infants. Moreover there are potential benefits in using specific nutrients: supplementation with long chain polyunsaturated fatty acids could decrease lung inflammation injuries, glutamine is the main source of energy of pneumocyte, vitamin A is essential for lung development, inositol is necessary for surfactant synthesis, vitamin E and selenium have anti-oxidant effects. Controlled nutritional trial are needed with a long term follow-up in late childhood in order to test their effects on growth and pulmonary status.
Collapse
Affiliation(s)
- L Bott
- Clinique de pédiatrie, hôpital Jeanne-de-Flandre, Lille, France
| | | | | | | | | |
Collapse
|
21
|
Blanaru JL, Kohut JR, Fitzpatrick-Wong SC, Weiler HA. Dose response of bone mass to dietary arachidonic acid in piglets fed cow milk-based formula. Am J Clin Nutr 2004; 79:139-47. [PMID: 14684410 DOI: 10.1093/ajcn/79.1.139] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The addition of arachidonic acid (AA) and docosahexaenoic acid (DHA) to infant formula was recently approved in North America. In piglets, dietary AA is linked to elevations in bone mass. OBJECTIVE The objective was to investigate the effects of varied amounts of dietary AA on bone modeling and bone mass with the use of the piglet model for infant nutrition. DESIGN Male piglets (n = 32) were randomly assigned to receive 1 of 4 formulas supplemented with AA (0.30%, 0.45%, 0.60%, or 0.75% of fat) plus DHA (0.1% of fat) from days 5 to 20 of life. Measurements included biomarkers of bone modeling, fatty acid status, and whole-body and femur bone mineral content; bone area was measured by dual-energy X-ray absorptiometry. Differences among groups were detected with two-factor analysis of variance. Regression analyses were used to determine factors responsible for bone mineral content after dietary AA was accounted for. RESULTS Proportions of AA in plasma, liver, and adipose were modified by the dietary treatments, but bone modeling was not affected. Liver AA was positively related to plasma insulin-like growth factor 1 and calcitriol and urinary N-telopeptide. Whole-body bone mineral content was elevated in the piglets fed 0.60% and 0.75% AA and was best predicted by dietary AA and bone resorption. CONCLUSIONS This study confirms that dietary AA alters bone mass and clarifies the best amount of AA to add to the diet of pigs born at term. Because the amount of dietary DHA was held constant, whether other amounts of DHA are related to bone mass requires investigation.
Collapse
Affiliation(s)
- Janice L Blanaru
- Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, Canada
| | | | | | | |
Collapse
|
22
|
Burke A, Weiler H. The effect of prostaglandin E(2) (PGE(2)) and long-chain polyunsaturated fatty acids (LC PUFA) on bone formation in piglets: a model for bone growth in nutritional investigation. Prostaglandins Leukot Essent Fatty Acids 2002; 67:229-35. [PMID: 12401437 DOI: 10.1054/plef.2002.0424] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
This research investigates the effects of exogenous prostaglandin E(2) (PGE(2)) treatment and arachidonic acid supplementation on the rate of growth in modelling bone of piglets. The piglet is a good model for the study of infant nutrition and bone growth. PGE(2) and long-chain polyunsaturated fatty acid (LC PUFA) supplementation, alone and in combination, are shown to have little or no effect on cortical bone thickness. Though exogenous PGE(2) supplementation and LC PUFA supplementation may both be effective in promoting bone growth and mass in adults, they do not appear to have the same positive effect on bone growth in infancy over a short term. A dynamic model for bone growth in piglets is proposed here for the first time. This research adds to our knowledge of the relationship between the dynamic histology of bone, the rate of osteogenesis, and the link between nutrition and bone growth.
Collapse
Affiliation(s)
- A Burke
- Department of Anthropology, University of Manitoba, Winnipeg, Manitoba, Canada
| | | |
Collapse
|
23
|
Weiler HA, Kovacs H, Murdock C, Adolphe J, Fitzpatrick-Wong S. Leptin predicts bone and fat mass after accounting for the effects of diet and glucocorticoid treatment in piglets. Exp Biol Med (Maywood) 2002; 227:639-44. [PMID: 12192107 DOI: 10.1177/153537020222700813] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The role of leptin in neonatal growth and bone metabolism has been investigated, but not simultaneously. The objectives of this study were to determine if leptin relates to bone mass during rapid growth; if consumption of maternal milk is related to elevated circulating concentrations of leptin resulting in higher fat mass; and if glucocorticoids result in higher fat mass and reduced bone mass due to elevated leptin. Thirty-two piglets were randomized to either a suckling or milk substitute plus either dexamethasone (DEX) or placebo injection for 15 days beginning at 5 days of age. Milk and blood samples were obtained at baseline, and after 15 days, blood was sampled again for measurement of leptin and bone biochemistry. Weight at baseline plus weight and length after 15 days were recorded, followed by measurement of whole body bone mineral content, bone area, and fat mass using dual energy x-ray absorptiometry. At baseline, plasma leptin was elevated in suckled piglets. Piglets that suckled had elevated fat mass as did those who received DEX. However, DEX resulted in suppressed weight and length, bone mass, and bone metabolism. Leptin was similar among groups after the 15 days. After accounting for body size and treatment effects, piglet plasma leptin was predictive of bone and fat mass. Leptin circulating early postnatally is linked to body composition, specifically fat and bone mass. Elevations in fat mass and reductions in bone mass observed after 15 days of DEX treatment are not related to leptin metabolism. Both human and porcine neonates share similar characteristics with respect to relationships of leptin with fat and bone mass.
Collapse
Affiliation(s)
- Hope A Weiler
- Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, Manitoba, Canada R3T 2N2.
| | | | | | | | | |
Collapse
|
24
|
Abstract
Optimal development of the newborn depends on rapid accretion of substrate in the neonatal period, particularly in the premature infant. Steroids and infection not only induce catabolism, but associated endogenous responses reprioritize crucial substrate to restore homeostasis. The result is a protein/energy deficit and concomitant delay in growth and development. Innovative feeding strategies and novel therapies are needed to reduce the impact of catabolism in this population.
Collapse
|
25
|
Abstract
BACKGROUND Preterm infants are at risk for suboptimal growth and bone mineralization compared to infants born at term but long-term outcomes into early adulthood are unclear. AIMS To determine (1) if growth and nutrition in the first year of life significantly predict the outcomes measured at adulthood and (2) whole body and regional bone mineral content (BMC) of young adults who were born preterm and weighing <1500 g. STUDY DESIGN AND SUBJECTS In this descriptive follow-up study, subjects were born preterm and weighing <1500 g (n=25, 17.2+/-1.2 years of age) and originally participated in a 1-year follow-up study of infant growth or subjects born at term (n=25, 17.3+/-1.4 years of age). OUTCOME MEASURES In the preterm group, relationships of growth and nutrition in the first year of life with adult anthropometry and BMC were identified using correlation and regression analysis. Birth groups were compared for measurements of anthropometry and whole body and regional BMC obtained at adulthood using t-tests. RESULTS After correcting for the effects of bone area using regression, rate of weight gain had a positive relationship and days to regain birth weight a negative relationship to adult BMC. Young adults, born preterm, were significantly shorter with lower whole body BMC than of those born at term, but BMC was appropriate for size. CONCLUSIONS Growth early in life predicts subsequent attainment of growth and bone mass. Premature birth results in lower attainment of height achieved by young adult age but bone mass is appropriate for body size.
Collapse
Affiliation(s)
- H A Weiler
- Department of Foods and Nutrition, University of Manitoba, Winnipeg, Manitoba, Canada R3T 2N2.
| | | | | |
Collapse
|
26
|
Loui A, Raab A, Obladen M, Brätter P. Calcium, phosphorus and magnesium balance: FM 85 fortification of human milk does not meet mineral needs of extremely low birthweight infants. Eur J Clin Nutr 2002; 56:228-35. [PMID: 11960298 DOI: 10.1038/sj.ejcn.1601305] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2001] [Revised: 07/05/2001] [Accepted: 07/09/2001] [Indexed: 11/09/2022]
Abstract
OBJECTIVE Extremely low birthweight (<1000 g) infants are growing rapidly and their nutritional requirements for calcium, phosphorus, magnesium are high. DESIGN Prospective, mineral balance. SETTING The study was carried out at the Department of Neonatology, Virchow-Hospital, Charité Berlin and the Department of Molecular Trace Element Research, Hahn-Meitner-Institute Berlin. SUBJECTS Nineteen infants <1000 g birthweight were admitted, nine infants dropped out and 10 infants (birthweight 730-995 g), fed fortified human milk were included. INTERVENTION We collected infant's urine and feces for 72 h, a sample of human milk and infant's blood at 7 and 12 weeks of age. Elements were measured by inductively coupled plasma atomic emission spectrophotometry. RESULTS Mean (s.d.) mineral concentration in milk was low especially at 12 weeks: calcium 9.88 (+/-3.58) mmol/l, phosphorus 7.02 (+/-3.81) mmol/l, magnesium 1.59 (+/-0.54) mmol/l. Calcium retention was minimal or negative during the study, whereas phosphorus and magnesium balances were positive. Caffeine and diuretics increased mineral excretion. Serum alkaline phosphatase was mostly <800 U/l, and 162 U/l in one infant with zinc deficiency at 12 weeks. Alkaline phosphatase correlated with absorption and retention of phosphorus, and with longitudinal growth. CONCLUSIONS Infants <1000 g have high nutritional needs for calcium, phosphorus and magnesium, which are not met by a human milk fortifier widely used in Europe. Controlled trials are needed to assess requirements, duration and risks of mineral supplementation.
Collapse
Affiliation(s)
- A Loui
- Department of Neonatology, Charité Virchow-Hospital, Humboldt University Berlin, Germany.
| | | | | | | |
Collapse
|
27
|
Weiler HA, Fitzpatrick-Wong S. Dietary long-chain polyunsaturated fatty acids minimize dexamethasone-induced reductions in arachidonic acid status but not bone mineral content in piglets. Pediatr Res 2002; 51:282-9. [PMID: 11861931 DOI: 10.1203/00006450-200203000-00004] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The primary objective of this study was to determine whether exogenous arachidonic acid (AA) in a supplemented formula substitute for piglets or sow milk would attenuate reductions in AA status, growth, and bone mineral content (BMC) as a result of exogenous glucocorticoid excess using dexamethasone (DEX). A secondary objective was to confirm a positive effect of exogenous AA on growth and BMC of piglets fed formula and not treated with DEX as well as to determine whether the elevation in BMC was related to greater production of prostaglandin E(2) in bone. Forty-eight 5-d-old male piglets were randomized to be suckled or receive either a standard formula or the same formula, but containing AA (0.5% wt/wt total fat) for 15 d in addition to either treatment with DEX or placebo. Piglets treated with DEX grew slower and had lower BMC of whole body, lumbar spine, and femur in addition to lower proportions of AA, but those fed standard formula had the greatest reductions. Piglets in the supplemented group weighed more than piglets fed standard formula or suckled in both the DEX and placebo groups. Suckled piglets had the highest BMC of whole body and femur compared with standard formula, and the supplemented group was intermediate for whole body but similar to suckled pigs for femur. Release of prostaglandin E(2) was elevated only with supplementation of AA. These data indicate that supplemental AA is associated with elevated whole body and femur BMC but that BMC is not enhanced during glucocorticoid treatment.
Collapse
Affiliation(s)
- Hope A Weiler
- Department of Foods and Nutrition, University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada.
| | | |
Collapse
|
28
|
Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr 2002. [PMID: 11841046 DOI: 10.1177/0148607102026001011] [Citation(s) in RCA: 365] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
29
|
Atkinson SA. Special nutritional needs of infants for prevention of and recovery from bronchopulmonary dysplasia. J Nutr 2001; 131:942S-946S. [PMID: 11238791 DOI: 10.1093/jn/131.3.942s] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Extremely low birth weight infants who develop severe respiratory disease may have special nutrient requirements imposed by a combination of enhanced utilization of nutrients or the need for epithelial cell repair resulting from the disease process, as well as to support catch-up growth. Inositol, free fatty acids, vitamin E and vitamin A are proposed as nutrients for which infants at risk of chronic pulmonary insufficiency may have special requirements. Of these nutrients, only for vitamin A does suggestive evidence exist that high doses when given intramuscularly may reduce the incidence of death or chronic lung disease. Exogenous steroid therapy (dexamethasone), which is often used to improve pulmonary compliance in ventilated premature infants, may compromise vitamin A status and induce restricted somatic and bone mineral growth. Supplemental nutrition by means of enriched infant formulas has provided benefits in growth and bone mass accretion to infants recovering from bronchopulmonary dysplasia up to 3-mo corrected age. This growth advantage was not sustained over the subsequent 9 mo, suggesting that prolonged nutritional support is required until catch-up growth is complete. Further studies are required to delineate the needs for specific nutrients such as antioxidant vitamins and minerals or vitamin A that may play a role in preventing severe chronic lung disease in premature infants. As well, the role of supplemental nutrition (beyond the requirements of term infants) to support catch-up growth and maintenance during the critical stages of early development requires further investigation before evidence-based nutrient recommendations can be developed for this special population of infants.
Collapse
Affiliation(s)
- S A Atkinson
- McMaster University, Department of Pediatrics, Faculty of Health Sciences, HSC 3V42, 1200 Main St. West, Hamilton, Ontario, Canada L8N 3Z5.
| |
Collapse
|
30
|
Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 2001; 1:1. [PMID: 11248841 PMCID: PMC29104 DOI: 10.1186/1471-2431-1-1] [Citation(s) in RCA: 262] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2000] [Accepted: 02/27/2001] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Recent reports have raised concerns that postnatal steroids may cause neuro-developmental impairment in preterm infants. This systematic review was performed with the objective of determining whether glucocorticoid therapy, to prevent or treat bronchopulmonary dysplasia, impairs neuro-developmental outcomes in preterm infants. METHOD A systematic review of the literature was performed. Medline was searched and articles retrieved using predefined criteria. Data from randomized controlled trials with adequate neuro-developmental follow up (to at least one year) were entered into a meta-analysis to determine the effects of postnatal treatment of preterm infants with glucocorticoids. Cerebral palsy rates, and neuro-developmental impairment (developmental score more than 2SD below the mean, or cerebral palsy or blindness) were analyzed. The studies were divided into 2 groups according to the extent of contamination of the results by treatment of controls with steroids after the initial study period, those with less than 30% contamination, and those with more than 30% contamination or size of contamination not reported. RESULTS Postnatal steroid therapy is associated with an increase in cerebral palsy and neuro-developmental impairment. The studies with less contamination show a greater effect of the steroids, consistent with a real direct toxic effect of steroids on the developing central nervous system. The typical relative risk for the development of cerebral palsy derived from studies with less than 30% contamination is 2.86 (95% CI 1.95, 4.19). The typical relative risk for the development of neuro-developmental disability among followed up infants from studies with less than 30% contamination is 1.66 (95% CI 1.26, 2.19). From this subgroup of studies, the number of premature infants who need to be treated to have one more infant with cerebral palsy (number needed to harm, NNH) is 7; to have one more infant with neuro-developmental impairment the NNH is 11. CONCLUSIONS Postnatal pharmacologic steroid treatment for prevention or treatment of bronchopulmonary dysplasia is associated with dramatic increases in neuro-developmental impairment. As there is no clear evidence in the literature of long term benefit, their use for this indication should be abandoned.
Collapse
Affiliation(s)
- K J Barrington
- Royal Victoria Hospital, 687 Pine Ave W, Room C7.68, Montreal, Quebec, H3A 1A1 Canada.
| |
Collapse
|
31
|
Kurl S, Heinonen K, Länsimies E. Effects of prematurity, intrauterine growth status, and early dexamethasone treatment on postnatal bone mineralisation. Arch Dis Child Fetal Neonatal Ed 2000; 83:F109-11. [PMID: 10952703 PMCID: PMC1721150 DOI: 10.1136/fn.83.2.f109] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
AIM To examine the hypothesis that, apart from prematurity, intrauterine growth status (expressed as gestational age specific birth weight standard deviation scores), neonatal factors, and duration of dexamethasone treatment influence bone mineralisation in early infancy. METHODS In this prospective study, groups consisted of 15 preterm small for gestational age infants (SGA group) and 43 preterm appropriate for gestational age infants (AGA group). A reference group contained 17 term infants. Body size is known to affect bone mineral content (BMC), therefore postnatal bone mineralisation was measured when the study infants and controls had attained a similar body size. Bone mineral density (BMD) and BMC were determined by dual energy x ray absorptiometer of the lumbar spine (L2-L4). RESULTS Both preterm groups had significantly lower BMC and BMD than the weight matched term reference group, but no difference was found in BMC and BMD between preterm SGA and AGA infants. In stepwise regression analysis, bone area, duration of dexamethasone treatment, weight at examination, and weight gain per week were the most significant factors, explaining 54% of the variance of the BMC values. CONCLUSION In particular, weight at examination, prematurity, and possibly dexamethasone treatment, but not intrauterine growth status, affect postnatal bone mineralisation.
Collapse
Affiliation(s)
- S Kurl
- Department of Paediatrics, Kuopio University Hospital, PO Box 1777, 70211 Kuopio, Finland.
| | | | | |
Collapse
|
32
|
Guo CY, Ward W, Cairns P, Atkinson S. Comparative response in growth and bone status to three dexamethasone treatment regimens in infant piglets. Pediatr Res 2000; 48:238-43. [PMID: 10926301 DOI: 10.1203/00006450-200008000-00019] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The objectives of this study were 1) to determine whether a zenith in bone formation (indicated by circulating osteocalcin) existed at night in early life, and 2) to compare the effects of three different dexamethasone (DEX) treatment regimens on bone turnover, bone mineral content, and growth. Three DEX treatment regimens were tested in 8-d-old piglets (n = 8/group): 1) low evening dose of DEX (0.5 mg/kg/d) as 70% in the morning and 30% in the evening for 10 d; 2) tapering course of DEX (0.5, 0.3, and 0.2 mg/kg/d) as 50% in the morning and 50% in the evening for 14 d; and 3) constant dose of DEX (0.5 mg/kg/d) as 50% in the morning and 50% in the evening for 10 d. Oral water placebo groups were tested with the same time courses. At pretreatment, plasma osteocalcin was significantly higher (p < 0.05) at 0100 than at 0900 and 1700. At necropsy, measures for DEX groups were calculated as Z-scores using values from the placebo groups. The low evening DEX dose led to a significantly lower reduction in plasma osteocalcin compared with the tapered and constant dosing regimens (p < 0.05). The significant weight. reduction in the DEX group occurred at d 9 in the low evening dose regimen but at d 7 in the constant dosing regimen, compared with the placebo group. Bone mineral content Z-score was reduced similarly in all DEX-treated groups across the three dosing regimens. We conclude that a plasma osteocalcin zenith at night exists in early life. A high DEX dose in the morning and low DEX dose in the evening may partially attenuate corticosteroid-induced suppression of bone formation and growth restriction.
Collapse
Affiliation(s)
- C Y Guo
- Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
| | | | | | | |
Collapse
|
33
|
Crofton PM, Shrivastava A, Wade JC, Stephen R, Mcintosh N, Lyon AJ. Effects of dexamethasone treatment on bone and collagen turnover in preterm infants with chronic lung disease. Pediatr Res 2000; 48:155-62. [PMID: 10926289 DOI: 10.1203/00006450-200008000-00007] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Dexamethasone is used commonly in the treatment of chronic lung disease of prematurity, but there are concerns about possible deleterious effects on growth and bone. Our aim in this study was to examine the effects of dexamethasone treatment on bone and collagen turnover in preterm infants. Bone-specific alkaline phosphatase, the C-terminal propeptide of type I collagen (PICP, reflecting whole-body type I collagen synthesis), and the N-terminal propeptide of type III procollagen (P3NP, reflecting soft tissue collagen turnover), together with the C-terminal telopeptide of type I collagen (ICTP), urinary pyridinoline (Pyd), and deoxypyridinoline (all markers of collagen breakdown) were measured at weekly intervals over the first 12 wk of life in 14 preterm infants with chronic lung disease treated with dexamethasone. Results were expressed as SD scores relative to preterm control infants not treated with dexamethasone. PICP, P3NP, ICTP, and Pyd all showed marked decreases (-2.1 to -3.7 SD scores) during the first week of treatment (p < 0.001), returning to pretreatment levels after stopping dexamethasone. In the group as a whole, these collagen markers were negatively correlated with dexamethasone dose (p < 0.0001); negative correlations were also seen in most individual babies, although the slopes of individual regression lines varied by a factor of 2. Weight gain at 12 wk was correlated with PICP, expressed as the mean SD score over 12 wk for each baby, (r = 0.69, p < 0.01) but not with other markers or cumulative dose of dexamethasone. We conclude that dexamethasone markedly suppressed collagen turnover in preterm infants in a dose-dependent fashion, although some babies were more affected than others. The degree of suppression of type I collagen synthesis was a strong independent predictor of overall weight gain over the first 12 wk of life.
Collapse
Affiliation(s)
- P M Crofton
- Department of Paediatric Biochemistry, Royal Hospital for Sick Children, Edinburgh, United Kingdom
| | | | | | | | | | | |
Collapse
|
34
|
Brook CG. Antenatal treatment of a mother bearing a fetus with congenital adrenal hyperplasia. Arch Dis Child Fetal Neonatal Ed 2000; 82:F176-81. [PMID: 10794782 PMCID: PMC1721096 DOI: 10.1136/fn.82.3.f176] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- C G Brook
- London Centre for Paediatric Endocrinology, Great Ormond Street Hospital for Children and The Middlesex Hospital, London, UK.
| |
Collapse
|
35
|
Weiler HA. Dietary supplementation of arachidonic acid is associated with higher whole body weight and bone mineral density in growing pigs. Pediatr Res 2000; 47:692-7. [PMID: 10813598 DOI: 10.1203/00006450-200005000-00022] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Essential fatty acids are fundamental to normal growth and development, but North American formulas do not contain arachidonic (AA) and docosahexaenoic acid (DHA). The main objective of the present study was to determine whether addition of AA and DHA to formula elevates growth and bone mineralization in piglets. A secondary objective was to establish whether liver fatty acid composition is related to that of bone. Twelve 10-d-old male piglets were randomized to receive either a standard formula with an n-6:n-3 fatty acid ratio of 4.9:1.0 or the same formula made with an equal amount of fat but containing AA (0.5% wt/wt total fat) and DHA (0.1% wt/wt total fat) for 14 d. Piglets in the supplemented group had significantly (p < 0.05) higher weight and greater bone mineral density of the whole body, lumbar spine, and femur. No differences were observed in whole body length, calcium absorption, or biochemical markers of bone metabolism. Feeding AA resulted in lower linoleic acid (p < 0.05) and higher (p < 0.05) AA in liver total lipid (% wt/wt) and bone FFA (% wt/wt) but no change to DHA. Liver AA (% wt/wt total lipid) was positively related (p < 0.05) to growth, free AA (% wt/wt) in bone, bone mineral content, bone mineral density, and urinary prostaglandin E2 but negatively related (p < 0.05) to free linoleic acid in bone. Inverse relationships were observed when liver linoleic acid was substituted for liver AA as the independent variable. These data indicate that feeding AA is associated with elevated weight and higher whole body and regional bone mineral density.
Collapse
Affiliation(s)
- H A Weiler
- Department of Foods and Nutrition, University of Manitoba, Winnipeg, Canada
| |
Collapse
|
36
|
Atkinson SA, Randall-Simpson J. Factors influencing body composition of premature infants at term-adjusted age. Ann N Y Acad Sci 2000; 904:393-9. [PMID: 10865777 DOI: 10.1111/j.1749-6632.2000.tb06488.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
We investigated the influence of body size at birth, feeding of mother's milk versus formula, or standard-term formula versus energy- or nutrient-enriched formula on the growth and whole body bone mineral content (BMC), lean and fat mass (using dual-energy X-ray absorptiometry) of low-birth-weight (LBW) infants to term-adjusted age. LBW infants who were appropriate for gestational age were lighter and shorter than term-born infants (n = 46) but had a higher percent fat mass (19-28% vs. 15 +/- 7%). For LBW infants fed standard formula or mother's milk after hospital discharge, the mean BMC expressed either as a function of weight (17 +/- 2, 19 +/- 2 vs. 20 +/- 2 g/kg) or length (1.1 +/- 0.2, 1.1 +/- 0.2 vs. 1.5 +/- 0.2 g/cm) was more than 1 SD below term infant values. However, infants fed a nutrient-enriched formula from hospital discharge had BMC within 1 SD below term infants. Infants who were born small, compared to appropriate for gestational age, compared to infants of similar birth weight had lower percent body fat (16 +/- 6 vs. 19 +/- 5) and lower BMC (47 +/- 3 vs. 62 +/- 5 g) at term age. Both size at birth and diet influence patterns of growth and body composition in early life in very-low-birth-weight (VLBW) infants. The long-term significance of these variable growth patterns in VLBW infants in early life requires further investigation.
Collapse
Affiliation(s)
- S A Atkinson
- Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.
| | | |
Collapse
|
37
|
Abstract
Clinical practice demands knowledge of gastrointestinal ontogeny and the factors that affect our ability to use enteral feeding in the micropremie. The decisions regarding milk type (when and how it should be given) are considered in the light of current physiologic and clinical evidence. Special considerations apply in the micropremie who is also small for gestational age and NEC must be avoided. Trophic feeding now has an established role, allowing the infant to benefit from enteral feeds even when full nutritive milk feeding is not possible.
Collapse
Affiliation(s)
- S J Newell
- Department of Neonatal Medicine, St. James's University Hospital, West Yorkshire, United Kingdom.
| |
Collapse
|
38
|
Rigo J, De Curtis M, Pieltain C, Picaud JC, Salle BL, Senterre J. Bone mineral metabolism in the micropremie. Clin Perinatol 2000; 27:147-70. [PMID: 10690569 DOI: 10.1016/s0095-5108(05)70011-7] [Citation(s) in RCA: 86] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Environmental factors, nutritional supplies, hormonal status, diseases, and treatments appear to affect postnatal skeletal growth and mineralization in VLBW infants. Compared with their term counterparts, ELBW infants are at risk of postnatal growth deficiency and osteopenia at the time of hospital discharge. From recent data, DXA is becoming one of the reference techniques to evaluate mineral status, whole-body composition, and effects of dietary manipulations on weight gain composition and mineral accretion in preterm infants. Weight gain and length increases need to be evaluated carefully during the first weeks of life, in the intensive care unit and out of it, in the step down unit. Nutritional survey is required to improve the nutritional supply and to maximize linear growth. As the critical epoch of growth extends, during the first weeks or months after discharge, follow-up and nutritional support need to be provided during the first years to promote early catch-up growth and mineralization. Further studies need to determine precisely the most optimal feeding regimen during this period but also need to evaluate the long-term implications of such a policy on stature, peak bone mass, and general health at adulthood.
Collapse
Affiliation(s)
- J Rigo
- Department of Pediatrics, University of Liège, CHR Citadelle, Belgium.
| | | | | | | | | | | |
Collapse
|
39
|
Cole CH. Postnatal glucocorticosteroid therapy for treatment and prevention of neonatal chronic lung disease. Expert Opin Investig Drugs 2000; 9:53-67. [PMID: 11060660 DOI: 10.1517/13543784.9.1.53] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Neonatal chronic lung disease (CLD) is a persistent complication, primarily of premature infants. Postnatal glucocorticoid therapy is widely used in the treatment and prevention of CLD. Most studies reveal acute improvement in the pulmonary status of infants treated with postnatal glucocorticoid therapy. Recent studies of 'earlier' intervention (< 14 days of age) demonstrated a reduction in mortality and in the occurrence of CLD between 28 days of age and 36 weeks postmenstrual age. Great concern remains, however, regarding the potential adverse outcomes, including growth inhibition, infection, catastrophic GI complications and CNS injury. Therefore, the use of postnatal glucocorticoid therapy remains controversial with respect to the clinical indications for initiating therapy, the dose, duration, onset and route of administration, as well as potential benefits and risks. Inhaled glucocorticoid therapy is increasingly used to treat and prevent CLD in order to avoid adverse effects of high dose systemic glucocorticoid therapy. Recent studies with inhaled glucocorticoid therapy show promise. Further work, however, for improving aerosol delivery and deposition, will be needed to refine their role in the prevention and treatment of CLD. Future studies enabling early, accurate identification of infants at greatest risk for CLD, coupled with a more comprehensive understanding of the different pathogeneses, will provide information regarding appropriate timing of onset, dosing, route of therapy and duration of intervention.
Collapse
Affiliation(s)
- C H Cole
- Department of Pediatrics, Tufts University School of Medicine, Boston Floating Hospital for Children, New England Medical Center, Boston, MA, USA.
| |
Collapse
|
40
|
Ward WE, Atkinson SA, Donovan SM, Paes B. Bone metabolism and circulating IGF-I and IGFBPs in dexamethasone-treated preterm infants. Early Hum Dev 1999; 56:127-41. [PMID: 10636592 DOI: 10.1016/s0378-3782(99)00039-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
AIM To characterize the ontogeny of circulating IGF-I, the IGF binding proteins (IGFBPs) and biochemical markers of bone turnover in dexamethasone (DEX)-treated preterm infants with chronic lung disease. METHODS Plasma and urine samples from 17 infants were obtained prior to DEX, after 9-12 days of DEX and 10 days after the completion of DEX to assess plasma IGF-I, IGFBPs, osteocalcin and urinary N-telopeptide. Nutrient intakes and growth were monitored from birth until term corrected age at which time body composition was evaluated by dual energy X-ray absorptiometry. RESULTS Although nutrient intakes did not differ during or after DEX, weight gain (115 vs. 174 g/week) and length gain (0.7 vs. 1.0 cm/week) were higher after DEX treatment. Plasma IGF-I, IGFBP-3 and osteocalcin increased over time. N-telopeptide was the only biochemical parameter which appeared to be suppressed during DEX (1342 nM bone collagen equivalents/mM creatinine vs. 2486 (pre-DEX) and 2292 (post-DEX)). At term corrected age, bone mineral content was lower in dexamethasone-treated infants compared to preterm and term reference infants. CONCLUSION Changes in circulating IGFBP-2 and IGFBP-3 paralleled the changes reported in non-steroid-treated infants; however, it remains uncertain whether the natural rise in IGF-I was suppressed by DEX treatment. Assessment of these circulating components provided limited insight into the mechanisms by which DEX alters growth and bone turnover.
Collapse
Affiliation(s)
- W E Ward
- Department of Pediatrics, Children's Hospital, Hamilton Health Sciences Corporation, McMaster University, Ontario, Canada
| | | | | | | |
Collapse
|
41
|
Leitch CA, Ahlrichs J, Karn C, Denne SC. Energy expenditure and energy intake during dexamethasone therapy for chronic lung disease. Pediatr Res 1999; 46:109-13. [PMID: 10400143 DOI: 10.1203/00006450-199907000-00018] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Dexamethasone is commonly administered to ventilator-dependent preterm infants with chronic lung disease. Infants receiving dexamethasone therapy frequently exhibit decreased rates of weight gain. The purpose of this investigation was to determine whether decreased growth in infants receiving dexamethasone therapy is caused by increased energy expenditure. Twelve infants were studied: 6 received dexamethasone treatment at 2 wk of age and crossed over to receive placebo treatment at 4 wk; the treatment order was reversed in the other 6 infants. The doubly labeled water method was used to determine energy expenditure for a 1-wk period during each treatment phase. The rate of weight gain during dexamethasone treatment was 6.5+/-10.6 and 20.0+/-5.7 g/kg/d during placebo treatment. Energy expenditure was 93.1+/-34.6 kcal/kg/d during dexamethasone treatment and 88.3+/-37.1 kcal/kg/d during placebo treatment. Energy intake was 119.2+/-29.0 kcal/kg/d during dexamethasone treatment and 113.8+/-23.7 kcal/kg/d during placebo treatment. The difference between intake and expenditure, or the energy available for growth, was 26.2+/-36.8 kcal/kg/d during dexamethasone treatment and 25.5+/-37.4 kcal/kg/d during placebo treatment. No significant differences were found in energy expenditure or energy intake between the treatment phases. The reduced growth seen in infants receiving dexamethasone treatment cannot be explained by increased energy expenditure or decreased energy intake, but may be due to differences in the composition of newly accreted tissue.
Collapse
Affiliation(s)
- C A Leitch
- Department of Pediatrics, Indiana University School of Medicine, Indianapolis 46202-5210, USA
| | | | | | | |
Collapse
|
42
|
Ward WE, Atkinson SA. Growth hormone and insulin-like growth factor-I therapy promote protein deposition and growth in dexamethasone-treated piglets. J Pediatr Gastroenterol Nutr 1999; 28:404-10. [PMID: 10204505 DOI: 10.1097/00005176-199904000-00011] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Abstract
BACKGROUND Dexamethasone treatment facilitates the weaning of premature infants from mechanical ventilation but impairs protein homeostasis, lean tissue deposition, and growth. The current study was conducted to investigate whether dexamethasone mediates these effects by reducing protein synthesis or elevating protein breakdown, and whether adjuvant growth hormone+/-insulin-like growth factor-I therapy can attenuate such effects. METHODS Piglets (n = 24) were randomized to placebo, a tapered course of dexamethasone (0.5, 0.3, 0.2 mg/kg per day for 5, 5 and 4 days each, respectively), dexamethasone + growth hormone 0.1 mg/kg per day, or dexamethasone + growth hormone + insulin-like growth factor-I 0.1 mg/kg per day for 14 days. On day 13, 15N-glycine was administered as a single oral dose, and urine was collected at timed intervals during the subsequent 48 hours. RESULTS Total urinary N and cumulative 15N excretion were higher in all dexamethasone groups than in control subjects. Protein synthesis was suppressed, whereas protein breakdown was unaltered by dexamethasone. Adjunctive growth hormone+/-insulin-like growth factor-I therapy enhanced protein synthesis, but only combined therapy improved net protein gain compared with dexamethasone alone. Higher circulating insulin-like growth factor-I may have mediated the greater net protein gain. Blood urea nitrogen was elevated in all dexamethasone-treated groups at days 6 and 11 but was normalized by day 15 with adjunctive growth hormone+/-insulin-like growth factor-I. From a functional perspective, both adjunctive growth hormone and growth hormone+/-insulin-like growth factor-I partially attenuated the dexamethasone-induced reduction in weight and length gain but not in whole body lean and fat mass. CONCLUSION Adjunctive growth hormone+/-insulin-like growth factor-I therapy partially reverses the dexamethasone-induced reduction in protein synthesis, resulting in improved growth when given concurrently with a low tapering dose of dexamethasone.
Collapse
Affiliation(s)
- W E Ward
- Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
| | | |
Collapse
|
43
|
Abstract
In preterm neonates a large skeletal mineral deficit builds up between birth and 40 wk postconception. During the phase of catch-up growth between 40 and 60 wk postconception there is a catch-up in peripheral skeletal mineralization, so that by the age of 1 y the skeletal mineral content is similar in preterm and term infants, despite the former being smaller, a finding that has been replicated for lumbar spinal mineralization. Later follow-up studies suggest that this catch-up persists and mineralization remains appropriate for body size. However, given the continuing abnormal growth experience of former preterm individuals, it would still be important to examine their bone mineralization in early adulthood. A number of interventions can improve perinatal bone mineralization, but few studies examine their long-term effectiveness. One such study has suggested that a relatively poor mineral diet in this period is, counterintuitively, associated with a later advantage in skeletal mineralization. If this finding is repeatable, then it could result in a major change in nutrition strategy in the neonatal period.
Collapse
Affiliation(s)
- S Ryan
- Royal Liverpool Children's NHS Trust, Alder Hey Hospital, UK
| |
Collapse
|
44
|
Brunton JA, Saigal S, Atkinson SA. Growth and body composition in infants with bronchopulmonary dysplasia up to 3 months corrected age: a randomized trial of a high-energy nutrient-enriched formula fed after hospital discharge. J Pediatr 1998; 133:340-5. [PMID: 9738713 DOI: 10.1016/s0022-3476(98)70266-5] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
OBJECTIVES (1) To determine whether nutrient malabsorption or inadequate nutrient intake were involved in the cause of growth delay in patients with bronchopulmonary dysplasia, and (2) to determine whether a nutrient-enriched formula given to infants with bronchopulmonary dysplasia to 3 months corrected age improves the rate of growth with greater lean and bone mass accretion when compared with infants fed an isoenergetic standard infant formula. STUDY DESIGN A blinded, nutrition intervention trial of 60 preterm infants with bronchopulmonary dysplasia (birth weight, 866 +/- 169 g, gestational age, 26 +/- 1.5 weeks) randomized to either nutrient-enriched formula or standard formula. Growth, body composition, and nutrient retention were compared between groups by Student's t tests and analysis of covariance. RESULTS Infants fed the enriched formula had significantly greater nitrogen and mineral retention at 38 weeks' postmenstrual age, and only the infants fed enriched formula had zinc retention similar to the intrauterine accretion. At 3 months corrected age infants fed enriched formula attained greater length (P < .05), greater radial bone mineral content (P < .01), and greater lean mass (P < .01). The male infants in the enriched formula group had greater whole body bone mineral content than did male infants in the standard formula group (P = .02). CONCLUSIONS Greater linear growth and lean and bone mass in the enriched formula group suggests that infants with bronchopulmonary dysplasia attain faster "catch-up" growth when fed higher intakes of protein, calcium, phosphorus, and zinc than provided in standard proprietary formulas.
Collapse
Affiliation(s)
- J A Brunton
- Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
| | | | | |
Collapse
|
45
|
Ward WE, Donovan SM, Atkinson SA. Dexamethasone-induced abnormalities in growth and bone metabolism in piglets are partially attenuated by growth hormone with no synergistic effect of insulin-like growth factor-I. Pediatr Res 1998; 44:215-21. [PMID: 9702917 DOI: 10.1203/00006450-199808000-00013] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Dexamethasone (DEX) therapy improves pulmonary compliance in premature infants with chronic lung disease; however, normal growth and bone development are impaired. Because DEX may mediate its effects by altering the GH-IGF-I axis, we investigated whether adjunctive therapy with GH or GH + IGF-I during DEX therapy could attenuate these DEX-induced effects. Piglets were randomized to placebo, oral tapered DEX (0.5, 0.3, and 0.2 mg kg(-1) d(-1) over 14 d), DEX + GH (0.1 mg kg(-1) d(-1)) or DEX + GH + IGF-I (0.1 mg kg(-1) d(-1)). Final whole body weight and length were improved with GH or GH + IGF-I compared with the DEX alone group. Plasma GH and IGF-I were not influenced by DEX, but infusion of IGF-I resulted in higher (p < 0.05) plasma IGF-I compared with all other groups at d 15. DEX reduced (p < 0.05) circulating IGFBP-2 and IGFBP-3 and liver IGFBP-2 and IGFBP-4 mRNA expression compared with controls. Treatment with DEX alone resulted in lower (p < 0.05) plasma osteocalcin, urinary N-telopeptide, and whole body and femur bone mineral density compared with controls, whereas results with piglets receiving adjunctive GH or GH + IGF-I were similar to those of controls. Given adjunctively, GH alone appears to partially counter the abnormalities in growth and bone metabolism associated with DEX therapy; however, this improvement cannot be attributed to higher circulating IGF-I, because combined therapy did not further improve growth or bone homeostasis compared with DEX + GH treatment. Growth hormone therapy has the potential to stimulate growth in infants exposed to steroid treatment.
Collapse
Affiliation(s)
- W E Ward
- Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
| | | | | |
Collapse
|
46
|
Fritz PC, Ward WE, Atkinson SA, Tenenbaum HC. Tamoxifen attenuates the effects of exogenous glucocorticoid on bone formation and growth in piglets. Endocrinology 1998; 139:3399-403. [PMID: 9681488 DOI: 10.1210/endo.139.8.6158] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Tamoxifen (Tam) has been shown to inhibit dexamethasone (Dex)-mediated effects on bone formation in vitro. Our objective was to determine whether Tam would block Dex-induced osteopenia and growth inhibition in growing piglets. Four-day-old male Yorkshire piglets were adapted to a liquid formula diet (400 ml/kg x day) and randomized to one of four groups (n = 5/group): Dex (0.5 mg/kg x day), Tam (1 mg/kg x day), Dex plus Tam, or placebo control (vehicle only). Both drugs were administered by orogastric gavage twice daily for 12 days. At baseline and at the end of treatment, whole body bone mineral density (BMD) was determined by dual energy x-ray absorptiometry (Hologic QDR1000W). Plasma osteocalcin and PTH were measured on days 0 and 12, and urinary N-telopeptide was measured on day 12. Changes in axial length and daily weight were also measured. Delta whole body BMD was 29% lower (P < 0.05) in Dex alone treated piglets than in controls (0.033 vs. 0.047 g/cm2, respectively), whereas the maximum change in BMD in Dex plus Tam group (0.046 g/cm2) was similar to that in controls. Concurrent Tam administration reduced the Dex-induced deficit in weight gain by 56% (P < 0.05) and the deficit in axial length gain by 72% (P < 0.01). In Dex alone treated piglets, PTH was significantly elevated (7-fold), whereas osteocalcin and N-telopeptide were significantly reduced compared with control values. These effects were prevented by Tam. These data suggest that the suppression of growth and other changes in parameters of bone metabolism induced by glucocorticoids in vivo can be attenuated by Tam.
Collapse
Affiliation(s)
- P C Fritz
- Medical Research Council Group in Periodontal Physiology, Faculty of Dentistry, University of Toronto, Ontario, Canada
| | | | | | | |
Collapse
|